- 专利标题: Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
-
申请号: US15233188申请日: 2016-08-10
-
公开(公告)号: US10376493B2公开(公告)日: 2019-08-13
- 发明人: Steven A. Rich
- 申请人: Qaam Pharmaceuticals, LLC
- 申请人地址: US NY Canandaigua
- 专利权人: Qaam Pharmaceuticals, LLC
- 当前专利权人: Qaam Pharmaceuticals, LLC
- 当前专利权人地址: US NY Canandaigua
- 代理机构: Brown & Michaels, PC
- 主分类号: A61K31/40
- IPC分类号: A61K31/40 ; A61K31/325 ; A61K31/27 ; A61K31/137 ; A61K31/216 ; C07D207/12 ; C07D451/00 ; A61K31/445 ; A61K31/435 ; A61K31/4015 ; A61K31/438 ; A61K31/165 ; A61K31/407 ; A61K31/20 ; A61K31/201 ; A61K31/202 ; A61K9/00 ; A61K9/70 ; A61K31/439
摘要:
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
公开/授权文献
信息查询